Relationships between uptake of [⁶⁸Ga]Ga-DOTA-TATE and absorbed dose in [¹⁷⁷Lu]Lu-DOTA-TATE therapy.

"Declarations Ethics approval and consent to participateImage data were obtained from two clinical trials, Iluminet (EudraCT No 2011–000240-16, Regionala etikprövningsnämnden Lund, Dnr 2011/287), Gapetto (EudraCT No 2012–004313-13, Regionala etikprövningsnämnden Lund, Dnr 2012/657). Complementary ethics approval was obtained for inclusion of patient data acquired after the closure of Gapetto (Etikprövningsmyndigheten Verksamhetsregion Lund, Dnr 2019–00564). Written informed consent for participation in the studies was obtained from all patients. All procedures performed were in accordance with the ethical standards of the institutional and national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments. Consent for publicationAll patients participating in the trials consented to their anonymized data being published in scientific journals prior to enrolment. Competing interestsKSG has participated in research project funded by Fusion Pharmaceuticals Inc, Canada, which does not affect this study. TO has received consultancy fee from Spago Nanomedical AB, Sweden. Competing interests KSG has participated in research project funded by Fusion Pharmaceuticals Inc, Canada, which does not affect this study. TO has received consultancy fee from Spago Nanomedical AB, Sweden."

"Funding Open access funding provided by Lund University. Economic support was granted by the Swedish Cancer Society (180747, 211754Pj01H) and Mrs. Berta Kamprad’s Foundation (BKS-2020-13) (KSG)."